Which factors should be considered in the selection of a phosphate-binding agent for the treatment of hyperphosphatemia in chronic kidney disease (CKD)?

Updated: Jul 21, 2021
  • Author: Pradeep Arora, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print
Answer

KDIGO guidelines suggest that the choice of phosphate-binding agent for the treatment of hyperphosphatemia take into account CKD stage, presence of other components of CKD mineral and bone disorder, concomitant therapies, and side-effect profile. [78] For adult patients, NICE guidelines recommend calcium acetate as the first-line phosphate binder to control serum phosphate, in addition to dietary management. [80] For full discussion of management, see Hyperphosphatemia.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!